Mesoblast (MSB)

Business description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Share price chart

Share chart

Stock data

Market cap.A$1298m
Last closeA$3.82
High / Low (52 weeks)A$5.8 / A$3.2
Stock market listingAU
Forecast net cash (A$m)153
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual9.1(8.6)(19.4)
Relative *12.6(5.7)(23.1)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BTG
Can-Fite BioPharma Capstone Therapeutics
Carmat Celldex Therapeutics
Cellectis Celyad
Cerulean Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals MethylGene
Midatech Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Here's why Mesoblast Limited shares soared 24% today

Mon, 13 Apr 2015 03:56:15 GMT

Key Mesoblast Patent Granted in the United States for the Treatment of ...

Mon, 09 Feb 2015 23:37:30 GMT

Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases ...

Thu, 26 Mar 2015 23:48:45 GMT

Mesoblast Cell Therapy Reduces Inflammation and Reverses Coronary Artery ...

Tue, 12 May 2015 02:03:45 GMT

Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal ...

Mon, 13 Apr 2015 00:05:42 GMT

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2013A 24.2 (58.7) (48.8) (17.21) N/A N/A
2014A 27.5 (77.4) (68.8) (21.53) N/A N/A
2015E 37.8 (92.0) (88.8) (26.14) N/A N/A
2016E 19.7 (101.4) (96.3) (28.37) N/A N/A

Last updated on 13/04/2015

Investment summary

Mesoblast recently announced a deal with US based Celgene. Celgene will purchase 15.3m shares (A$58.5m) at A$3.82 per share, also gaining the right for six month refusal to Mesoblast's proprietary stem cells in acute graft vs host disease (GVHD), certain oncologic diseases, inflammatory bowel disease and organ transplant rejection. The company's product pipeline continues to mature as key milestones are met. Phase III trials for MPV-06-ID in low back pain were recently initiated. The filing of MSC-100-IV by partner JCR Pharma in GVHD in Japan last October, marked Mesoblast's first product submission and a regulatory decision is likely in mid-2015. Filing is planned in paediatric aGvhD in 2016 in the US on the back of an open-label Phase III trial. Phase III trials also started in 2014 for MPC-150-IM in congestive heart failure. Interim data are expected in mid 2016 and top-line data in mid 2017.

Last updated on 06/05/2015

Industry outlook

Mesoblast is the leading mesenchymal stem cell development company, with two technology platforms (MPCs, MSCs) and nine clinical candidates in Phase III and Phase II. Its three alliances – with Teva, JCR and Lonza – underpin the key late-stage programmes.

Last updated on 06/05/2015

Key management

Company address

Level 39
55 Collins Street
Melbourne 3000
Australia
+61 3 9639 6036
View website